Showing results (41-50 of 95) with videos related to
Sort By:
Pageof 10
Current Urology|August 11, 2020
Predictive Ability for Disease-Free Survival of the GRade, Age, Nodes, and Tumor (GRANT) Score in Patients with Resected Renal Cell CarcinomaAlessio Cortellini, Sebastiano Buti, Melissa Bersanelli, et al.Cancers|September 9, 2020
Neoadjuvant Immune-Checkpoint Blockade in Triple-Negative Breast Cancer: Current Evidence and Literature-Based Meta-Analysis of Randomized TrialsDaniele Marinelli, Marco Mazzotta, Laura Pizzuti, et al.Oncotarget|October 6, 2017
Anthropometric, clinical and molecular determinants of treatment outcomes in postmenopausal, hormone receptor positive metastatic breast cancer patients treated with fulvestrant: Results from a real word settingLaura Pizzuti, Clara Natoli, Teresa Gamucci, et al.Journal of Thrombosis and Thrombolysis|March 29, 2019
Long-term performance of risk scores for venous thromboembolism in ambulatory cancer patientsMarcello Di Nisio, Nick van Es, Ludovica Rotunno, et al.International Journal of Molecular Sciences|May 21, 2020
Neoadjuvant Endocrine Therapy in Breast Cancer: Current Knowledge and Future PerspectivesGiacomo Barchiesi, Marco Mazzotta, Eriseld Krasniqi, et al.Journal of Cancer|November 26, 2019
Impact of primary tumor location in patients with RAS wild-type metastatic colon cancer treated with first-line chemotherapy plus anti-EGFR or anti-VEGF monoclonal antibodies: a retrospective multicenter studyAntonino Grassadonia, Pietro Di Marino, Corrado Ficorella, et al.Journal of Experimental & Clinical Cancer Research : CR|April 4, 2016
Topographic expression of the Hippo transducers TAZ and YAP in triple-negative breast cancer treated with neoadjuvant chemotherapyPatrizia Vici, Cristiana Ercolani, Anna Di Benedetto, et al.Cell Death Discovery|April 23, 2021
Tgf-β1 transcriptionally promotes 90K expression: possible implications for cancer progressionAntonino Grassadonia, Vincenzo Graziano, Sara Pagotto, et al.Journal of Molecular Medicine (Berlin, Germany)|August 7, 2012
LGALS3BP, lectin galactoside-binding soluble 3 binding protein, induces vascular endothelial growth factor in human breast cancer cells and promotes angiogenesisEnza Piccolo, Nicola Tinari, Daniela Semeraro, et al.Oncotarget|September 15, 2017
Fulvestrant 500 milligrams as endocrine therapy for endocrine sensitive advanced breast cancer patients in the real world: the Ful500 prospective observational trialLuca Moscetti, Maria Agnese Fabbri, Clara Natoli, et al.Pageof 10